Journal
CANCERS
Volume 11, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cancers11040436
Keywords
pheochromocytoma; paraganglioma; neuroendocrine tumor; targeted therapy; therapy resistance
Categories
Funding
- Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD USA
- NATIONAL CANCER INSTITUTE [ZIABC011684] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pheochromocytoma and paraganglioma (PCPGs) are rare neuroendocrine tumors that arise from the chromaffin tissue of adrenal medulla and sympathetic ganglia. Although metastatic PCPGs account for only 10% of clinical cases, morbidity and mortality are high because of the uncontrollable mass effect and catecholamine level generated by these tumors. Despite our expanding knowledge of PCPG genetics, the clinical options to effectively suppress PCPG progression remain limited. Several recent translational studies revealed that PCPGs with different molecular subtypes exhibit distinctive oncogenic pathways and spectrum of therapy resistance. This suggests that therapeutics can be adjusted based on the signature molecular and metabolic pathways of PCPGs. In this review, we summarized the latest findings on PCPG genetics, novel therapeutic targets, and perspectives for future personalized medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available